EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

27 November 2020
EMA/599224/2020
EMEA/H/C/000713

Public statement

Alpivab

Withdrawal of the marketing authorisation in the European Union

On 20 November 2020, the European Commission withdrew the marketing authorisation for Alpivab (peramivir) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, BioCryst Ireland Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Alpivab was granted a marketing authorisation in the EU on 13 April 2018 for the treatment of uncomplicated influenza in adults and children from the age of 2 years. The marketing authorisation was valid for a 5-year period. The product had not been marketed in the EU.

The European Public Assessment Report (EPAR) for Alpivab will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union